It Kills That: Cramer Won’t Recommend Pfizer 7% Yield
Jim Cramer declines to back Pfizer despite its 7% dividend, arguing the growth case isn’t clear. Pfizer sits near a 5...
Explore Watch Out For Withdrawal Limits Crypto to anticipate daily and weekly caps, fees, and batch transfer considerations.
25,202 articlesJim Cramer declines to back Pfizer despite its 7% dividend, arguing the growth case isn’t clear. Pfizer sits near a 5...
Amazon faces a cash-heavy growth cycle as cloud demand and custom chips drive revenue. The market clamps down on near...
Markets feel expensive, but Warren Buffett keeps it simple. This article explores the one low-cost investment he’s tr...
Investors are turning to the best railroad stocks as freight volumes stabilize and dividends prove resilient. The top...
Jim Cramer argues Meta's AI model shift delivered a roughly $100 per share move, illustrating why big tech remains ha...
Rising electricity costs driven by AI data centers are reshaping the landscape for utility stocks. This deep dive exp...
In mid-2026 market conditions test retirement plans built on dividend income. This piece weighs yield versus growth t...
Philanthropy headlines are buzzing as Warren Buffett shifts a long-standing gift pattern. This piece breaks down what...
Two AI-driven stocks with durable moats and solid cash flow could deliver outperformance over the next five years. Ex...
A high-profile insider sale by AeroVironment's CEO has investors asking what it means for the stock. This guide break...
Renewed Iran tensions push Treasury yields higher and lift mortgage costs, threatening affordability for buyers and h...
Inflation cooled june brought relief but also questions for investors. This guide breaks down what the data means, ho...